Cobalis Corp. (fka CLSC)

[MPTIU82]

YLA Global strategy once FDA approval not granted was to short the stock. Once Cobalis made no attempts to satisfy debt and had no plan in place to sell product, YLA/Cornell then wanted it in BK so as not to have to cover short postion; get the patent asset for Pre-Histin as debt repayment, and launch the product themselves thru their own partners. This business strategy of theirs is known and was avaialble to those present in court during the BK hearings.